USA: Strategic Partnership Biomotiv and Bristol-Myers Squibb Launch New Biotech Company

Biomotiv and Bristol-Myers Squibb Company announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

New York/USA — Biomotiv and Bristol-Myers Squibb have executed a Strategic Partnership Agreement in September 2019. Now, the partners have launched a first company, called Anteros Pharmaceuticals. It is the first of several companies that the two companies intend to form under the Strategic Partnership Agreement. The intellectual property behind Anteros was first developed by Yale University and in-licensed by Bristol-Myers Squibb and subsequently assigned to Anteros. According to Satish Jindal, Ph.D., Biomotiv’s CEO, Anteros will focus on refining a new class of drug candidates for inflammatory diseases, where currently there are no real answers to multiple diseases that afflict millions of patients.

Under the terms of the partnership, Bristol-Myers Squibb will contribute the IP, data, and reagents for a series of small molecules against an undisclosed mechanism, and Biomotiv, through the formation of Anteros Pharmaceuticals, working in close partnership with Yale, will be solely responsible for research and development. Once Anteros nominates a pre-clinical candidate, Bristol-Myers Squibb has the option to acquire the company from Biomotiv under pre-agreed terms.

This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46352702)